A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• SRC kinase plays a critical role in solid tumor progression and resistance.
• Current SRC inhibitors targeting kinase activity have not improved patient outcomes.
• SRC's dual enzymatic and scaffolding functions are implicated in cancer.

Purpose of the Study:

• To investigate the novel small molecule eCF506 as a potential therapeutic agent targeting SRC.
• To elucidate the mechanism of action of eCF506 in inhibiting SRC.
• To evaluate the efficacy and tolerability of eCF506 in preclinical cancer models.

Main Methods:

• Utilized a small molecule inhibitor, eCF506, designed to lock SRC in its inactive conformation.
• Assessed inhibition of SRC's enzymatic and scaffolding functions, including phosphorylation and FAK complex formation.
• Evaluated eCF506's potency and selectivity in vitro and in vivo.
• Tested antitumor efficacy and tolerability in syngeneic murine cancer models.

Main Results:

• eCF506 effectively inhibited both enzymatic and scaffolding functions of SRC.
• The molecule demonstrated potent and selective pathway inhibition in cellular and animal models.
• eCF506 treatment led to enhanced antitumor efficacy and improved tolerability.
• Preclinical results showed significant advantages over existing SRC/ABL inhibitors.

Conclusions:

• Inhibiting SRC through a mechanism that impairs both catalytic and scaffolding functions offers a promising therapeutic strategy.
• eCF506 demonstrates superior anticancer properties and tolerability compared to current SRC/ABL inhibitors.
• This novel approach to SRC inhibition holds potential for treating SRC-associated malignancies.